The insider sales, while not by C-suite executives, are material relative to market cap and come right after a strategic update that included an asset sale and debt repayment. The company's cash runway is limited ($46.5M at Q1 end) and it is actively seeking strategic alternatives — this could signal insider pessimism about the outcome. Watch for any 8-K regarding a potential sale, merger, or wind-down, and monitor cash burn in the next 10-Q.
Price Chart
Executive Summary
Two insiders at Werewolf Therapeutics sold a total of $299K in open-market sales over a 7-day window, representing ~0.9% of the company's $32M market cap. The sales follow the company's Q1 2026 earnings release, which disclosed a net loss of $13.5M, an asset sale to Jazz Pharmaceuticals, and repayment of all K2 debt, while the company continues to explore strategic alternatives. The cluster is notable for its size relative to market cap and the proximity to the earnings announcement, but the sales are by a director and a 10% owner, not C-suite executives.
Key Financial Metrics
Key Facts
- Total insider sales of $299K represent ~0.9% of $32M market cap — significant for a micro-cap biotech
- Sales occurred within 5 days of Q1 2026 earnings (May 7) and after Jazz asset purchase agreement and K2 debt repayment
- RA Capital Management (10% owner) sold 351.5K shares for $250K on May 8; Director Luke Evnin sold 93.7K shares for $60K on May 6-7
- Q1 2026 net loss was $13.5M vs $18.1M YoY; cash burn continues with $46.5M cash at quarter-end
- Company is exploring strategic options with Piper Sandler; no C-suite insiders sold in this cluster
Financial Impact
Insider sales of $299K represent 0.9% of market cap; Q1 net loss of $13.5M; cash burn rate ~$10M/quarter
Risk Factors
- Insider selling at 0.9% of market cap in a micro-cap biotech with limited cash runway is a bearish signal
- Company is exploring strategic alternatives — could result in a dilutive financing, asset sale at unfavorable terms, or wind-down
- No C-suite buying to offset selling; RA Capital is a significant holder reducing its position
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-HOWL-1778624823979 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-4/A | $0.9806 | awaiting T+5 | — | $1.02 (−4.02%) |
Sep 22, 2026 4w ago | S-4 | $0.9894 $0.9223 | ▲ +6.78% | ▲ +6.11% | $1.02 (−3.09%) |
Sep 21, 2026 5w ago | SC 13G | $0.9800 $0.9300 | ▼ −5.10% | ▼ −4.08% | $1.02 (+4.08%) |
Aug 21, 2026 9w ago | 425 | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $1.02 (+16.70%) |
Aug 21, 2026 9w ago | 8-K | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $1.02 (+16.70%) |
Aug 21, 2026 9w ago | Press Release | $0.8740 $0.9433 | ▼ −7.93% | ▼ −7.46% | $1.02 (−16.70%) |
Jul 31, 2026 12w ago | 8-K | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $1.02 (+188.87%) |
Jul 31, 2026 12w ago | Press Release | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $1.02 (+188.87%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $1.02 (−183.41%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $1.02 (−183.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers